The cell cycle regulator CDC25A is a target for JAK2V617F oncogene.

@article{Gautier2012TheCC,
  title={The cell cycle regulator CDC25A is a target for JAK2V617F oncogene.},
  author={Emilie-Fleur Gautier and Muriel Picard and Camille Laurent and Caroline Marty and J L Villeval and C Saura Demur and François Delhommeau and Elizabeth O Hexner and St{\'e}phane Giraudier and Nicolas Bonnevialle and Bernard Ducommun and Christian R{\'e}cher and Guy Laurent and St{\'e}phane Manenti and V{\'e}ronique Mansat-De Mas},
  journal={Blood},
  year={2012},
  volume={119 5},
  pages={1190-9}
}
The JAK2(V617F) mutation is present in the majority of patients with polycythemia vera and one-half of those with essential thrombocythemia and primary myelofibrosis. JAK2(V617F) is a gain-of-function mutation resulting in constitutive JAK2 signaling involved in the pathogenesis of these diseases. JAK2(V617F) has been shown to promote S-phase entry. Here, we demonstrate that the CDC25A phosphatase, a key regulator of the G1/S cell-cycle transition, is constitutively overexpressed in JAK2(V617F… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

How does JAK2V617F contribute to the pathogenesis of myeloproliferative neoplasms?

Hematology. American Society of Hematology. Education Program • 2014

Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2014
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 36 references

Similar Papers

Loading similar papers…